erlotinib hydrochloride has been researched along with isoxazoles in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (isoxazoles) | Trials (isoxazoles) | Recent Studies (post-2010) (isoxazoles) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 8,633 | 900 | 3,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandes, J; Jampol, LM; Johnson, ML; Mets, M; Munk, MR; Patel, JD | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA | 1 |
| de Vries, EGE; Giesen, D; Kol, A; Lub-de Hooge, MN; Pool, M; Terwisscha van Scheltinga, AGT | 1 |
| Banpurkar, AR; Perdih, F; Wazalwar, SS | 1 |
1 trial(s) available for erlotinib hydrochloride and isoxazoles
| Article | Year |
|---|---|
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome | 2015 |
4 other study(ies) available for erlotinib hydrochloride and isoxazoles
| Article | Year |
|---|---|
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
Topics: Adenocarcinoma; Aged; Autoantibodies; Autoantigens; Electroretinography; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Infusions, Intravenous; Isoxazoles; Lung Neoplasms; Male; Night Blindness; Paraneoplastic Syndromes, Ocular; Phosphopyruvate Hydratase; Quinazolines; Resorcinols; Retina; Tomography, Optical Coherence; Visual Acuity | 2014 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Feasibility Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Positron-Emission Tomography; Proto-Oncogene Proteins c-met; Radioisotopes; Resorcinols; Up-Regulation; Zirconium | 2017 |
Synthesis, crystal structure and molecular docking study of novel isoxazole derivatives as CYP450 inhibitors in search of anticancer agents.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Isoxazoles; Ketoconazole; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2023 |